文献速递细菌感染、耐药与抗菌药物

BSAC先锋系列:抗菌药物耐药性与诊断检测的未来

BSAC Vanguard Series: Antimicrobial resistance and the future of diagnostic testing.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

在英国,约80%的抗生素由全科诊所和其他社区机构开具。诊断技术有望在社区环境中推动抗菌药物管理的变革,但现有诊断在信息量和速度上均有限。需要开发成本低、速度快、能区分致病菌与定植菌的诊断方法,并为其提供适当资金支持、嵌入临床实践以改变处方行为,学术界与产业界的合作是关键。

要点

  • 英国约80%抗生素由全科诊所和其他社区机构开具。
  • 现有诊断在提供信息和速度上有限,需开发低成本、快速、能区分致病菌与定植菌的方法。
  • 诊断需适当资助并嵌入实践以改变处方行为,学术界与产业界合作是关键。

核心结论

  • 诊断技术有望在社区环境中推动抗菌药物管理的变革,但需开发成本低、速度快、能区分致病菌与定植菌的方法,并适当资助和嵌入实践以改变处方行为。

研究设计与样本

  • 本文为BSAC先锋系列文章,未报告系统检索范围或样本量。

主要发现

  • 在英国,约80%的抗生素由全科诊所和其他社区机构开具。
  • 现有诊断在可提供的信息量和速度方面对处方者有限。

临床怎么用

  • 作者认为需要开发足够廉价以大规模应用、足够快速以改变处方决策、并能检测引起疾病的细菌而非仅定植菌的诊断方法。
  • 作者认为这些诊断需获得适当资金支持,并以鼓励改变处方行为的方式嵌入实践。
  • 作者认为学术界与产业界的合作对于开发适用、证据充分且在这些环境中获得适当资助的检测至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the UK around 80% of all antibiotics are prescribed by GP surgeries and in other community settings. Diagnostic technology has the potential to enable transformative change to antimicrobial stewardship in these settings. Current diagnostics are limited in terms of the information they can provide prescribers and the speed they can provide it. We need to develop diagnostics that are cheap enough for mass application, rapid enough to change prescribing decisions and able to detect bacteria which are causing disease rather than simply resident in the host. To be successful in creating change these diagnostics need to be appropriately funded and embedded in practice in ways which encourage change in prescribing behaviours. Collaboration between academia and industry is key in developing tests which are fit for purpose, well evidenced and appropriately funded in these settings.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Hayward G, Turner P. BSAC Vanguard Series: Antimicrobial resistance and the future of diagnostic testing. J Antimicrob Chemother. 2022. PMID: 34849950. doi:10.1093/jac/dkab418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。